CJC-1295 and ipamorelin are two growth hormone-stimulating peptides that are frequently prescribed together because their mechanisms are complementary and their combined effect is significantly greater than either alone. For men interested in testosterone support, body recomposition, sleep quality, and metabolic function, this stack is one of the most clinically useful tools available.
Understanding the Two Peptides Separately
CJC-1295: The Sustained GHRH Analogue
CJC-1295 is a synthetic analogue of GHRH (growth hormone-releasing hormone), the hypothalamic signal that instructs the pituitary to release GH. The key modification in CJC-1295 (with DAC - drug affinity complex) is a molecular addition that dramatically extends its half-life from minutes to approximately 6 to 8 days.
This extended half-life means CJC-1295 provides a sustained GHRH stimulus, elevating basal GH release over time rather than producing a single sharp pulse.
Ipamorelin: The Selective GH Pulse Amplifier
Ipamorelin works through a different receptor (the ghrelin receptor), producing pulsatile GH release that mimics the natural amplitude of physiological GH bursts. It is highly selective for GH secretion without significantly elevating cortisol or prolactin.
Ipamorelin acts acutely, producing GH pulses in the hours after injection rather than sustained elevation.
Why the Combination Is Synergistic
CJC-1295 provides elevated tonic GH secretion throughout the day, while ipamorelin amplifies the amplitude of GH pulses at specific times. Together:
- CJC-1295 raises the baseline level of GH stimulation (floor effect)
- Ipamorelin adds acute pulsatile amplitude on top of that elevated baseline (peak amplification)
- The net result is a GH secretion profile significantly above what either peptide achieves alone, while remaining physiological in its pulsatile pattern
Multiple studies have confirmed that the CJC-1295 + ipamorelin combination produces IGF-1 elevations of 30 to 50 percent above baseline in GH-deficient adults, significantly greater than either peptide in isolation.
How the Stack Supports Testosterone
The stack supports testosterone through several pathways:
IGF-1 and Leydig Cell Support
IGF-1 produced in response to elevated GH acts on IGF-1 receptors in testicular Leydig cells. IGF-1 signalling is required for optimal Leydig cell function and enhances the testosterone synthesis response to LH stimulation.
Body Composition Improvement
Higher GH and IGF-1 increase lean mass and reduce visceral fat. Reduced visceral fat means less aromatase activity, less testosterone-to-oestradiol conversion, and higher effective testosterone levels.
Sleep Architecture Improvement
GH is released predominantly during slow-wave sleep. The stack enhances sleep quality and depth, which secondarily improves the nocturnal testosterone production that depends on adequate slow-wave sleep.
Reduced Cortisol Burden
Unlike some GH-stimulating peptides, ipamorelin does not raise cortisol. Maintaining lower cortisol reduces the direct suppression of testosterone that chronic cortisol elevation produces.
Dosing Protocol and Timing
At Longegra, the CJC-1295 and ipamorelin stack is typically administered as a subcutaneous injection before sleep. Night-time administration aligns with the natural GH pulsatility pattern, maximising the synergistic effect with sleep-related GH release.
Doses are based on your baseline IGF-1 level, with a follow-up test at three months to confirm response and adjust if needed.
How Long Before Results Are Seen?
- Sleep quality improvements: Often noticed within the first two to four weeks
- Energy and recovery: Typically improving at four to eight weeks
- Body composition changes: Measurable at three months with consistent use
- IGF-1 improvement: Confirmed by blood test at three months
- Testosterone support: Gradual, following body composition and sleep improvements over three to six months
Frequently Asked Questions (FAQs)
The combination is considered safe and well tolerated under physician supervision. Common mild effects include transient water retention and mild joint discomfort in the first few weeks, related to GH's action on fluid balance. These typically resolve within a month.
